Literature DB >> 10543736

Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

F Barbut1, D Decré, B Burghoffer, D Lesage, F Delisle, V Lalande, M Delmée, V Avesani, N Sano, C Coudert, J C Petit.   

Abstract

Glycopeptides (vancomycin and teicoplanin) and metronidazole are the drugs of choice for the treatment of Clostridium difficile infections, but trends in susceptibility patterns have not been assessed in the past few years. The objective was to study the MICs of glycopeptides and metronidazole for unrelated C. difficile strains isolated in 1991 (n = 100) and in 1997 (n = 98) by the agar macrodilution, the E-test, and the disk diffusion methods. Strain susceptibilities to erythromycin, clindamycin, tetracycline, rifampin, and chloramphenicol were also determined by the ATB ANA gallery (bioMérieux, La Balme-les-Grottes, France). The MICs at which 50% of isolates are inhibited (MIC(50)s) and MIC(90)s of glycopeptides and metronidazole remained stable between 1991 and 1997. All the strains were inhibited by concentrations that did not exceed 2 microgram/ml for vancomycin and 1 microg/ml for teicoplanin. Comparison of MICs determined by the agar dilution method recommended by the National Committee for Clinical Laboratory Standards and the E test showed correlations (+/-2 dilutions) of 86. 6, 95.9, and 99% for metronidazole, vancomycin, and teicoplanin, respectively. The E test always underestimated the MICs. Strains with decreased susceptibility to metronidazole (MICs, >/=8 microgram/ml) were isolated from six patients (n = 4 in 1991 and n = 2 in 1997). These strains were also detected by the disk diffusion method (zone inhibition diameter, </=21 mm); they belonged to nontoxigenic serogroup D (n = 5) and toxigenic serogroup H (n = 1). Decreased susceptibility to erythromycin (MICs, >/=1 microgram/ml), clindamycin (MICs, >/=2 microgram/ml), tetracycline (MICs, >/=8 microgram/ml), rifampin (MICs, >/=4 microgram/ml), and chloramphenicol (MICs, >/=16 microgram/ml) was observed in 64.2, 80.3, 23.7, 22.7, and 14.6% of strains, respectively. Strains isolated in 1997 were more susceptible than those isolated in 1991, and this trend was correlated to a major change in serogroup distribution. Periodic studies are needed in order to detect changes in serogroups and the emergence of strains with decreased susceptibility to therapeutic drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543736      PMCID: PMC89532     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Antimicrobial susceptibility of Clostridium difficile strains isolated from hospitalised patients with acute diarrhoea.

Authors:  S K Niyogi
Journal:  J Diarrhoeal Dis Res       Date:  1992-09

2.  Comparison of the E test and a reference agar dilution method for susceptibility testing of anaerobic bacteria.

Authors:  J Wüst; U Hardegger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

3.  Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains.

Authors:  S S Jang; L M Hansen; J E Breher; D A Riley; K G Magdesian; J E Madigan; Y J Tang; J Silva; D C Hirsh
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

4.  Susceptibility testing of anaerobes with Etest.

Authors:  A Bolmström
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

Review 5.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

6.  Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors.

Authors:  F Barbut; J L Meynard; M Guiguet; V Avesani; M V Bochet; M C Meyohas; M Delmée; P Tilleul; J Frottier; J C Petit
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-11-01

7.  Use of an enzyme-linked immunoassay for Clostridium difficile serogrouping.

Authors:  M Delmée; C Depitre; G Corthier; A Ahoyo; V Avesani
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

8.  Clostridium difficile colonization and diarrhea at a tertiary care hospital.

Authors:  M H Samore; P C DeGirolami; A Tlucko; D A Lichtenberg; Z A Melvin; A W Karchmer
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

9.  Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.

Authors:  C R Clabots; S Johnson; M M Olson; L R Peterson; D N Gerding
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

10.  Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

Authors:  F de Lalla; R Nicolin; E Rinaldi; P Scarpellini; R Rigoli; V Manfrin; A Tramarin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

View more
  21 in total

1.  Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Authors:  T Norén; M Wullt; Thomas Akerlund; E Bäck; I Odenholt; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection.

Authors:  L Alcalá; E Reigadas; M Marín; A Martín; P Catalán; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-24       Impact factor: 3.267

Review 4.  Management of adult Clostridium difficile digestive contaminations: a literature review.

Authors:  Fanny Mathias; Christophe Curti; Marc Montana; Charléric Bornet; Patrice Vanelle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-29       Impact factor: 3.267

Review 5.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 6.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

7.  gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.

Authors:  Larbi Dridi; Jacques Tankovic; Béatrice Burghoffer; Frédéric Barbut; Jean-Claude Petit
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 8.  The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge.

Authors:  E R Dubberke; D B Haslam; C Lanzas; L D Bobo; C-A D Burnham; Y T Gröhn; P I Tarr
Journal:  Zoonoses Public Health       Date:  2010-09-24       Impact factor: 2.702

9.  Clostridium difficile brain empyema after prolonged intestinal carriage.

Authors:  J Gravisse; G Barnaud; B Hanau-Berçot; L Raskine; J Riahi; J L Gaillard; M J Sanson-Le-Pors
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006.

Authors:  H Martin; B Willey; D E Low; H R Staempfli; A McGeer; P Boerlin; M Mulvey; J S Weese
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.